A phase I, open label, non-randomised study to evaluate the pharmacokinetics and safety of Pralatrexate in patients with relapsed refractory advanced solid tumors and lymphoma with mild, moderate and severe renal impairment
Latest Information Update: 14 Jun 2017
At a glance
- Drugs Pralatrexate (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 14 Jun 2017 New trial record